Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A

被引:6
|
作者
Miyazaki, Yuka [1 ]
Kikuchi, Masaki [2 ]
Umezawa, Koji [3 ]
Descamps, Aurelie [4 ]
Nakamura, Daichi [4 ]
Furuie, Gaku [1 ]
Sumida, Tomoe [4 ,6 ]
Saito, Kanako [1 ]
Kimura, Ninako [1 ]
Niwa, Takashi [4 ]
Sumida, Yuto [4 ,6 ]
Umehara, Takashi [2 ]
Hosoya, Takamitsu [4 ,5 ]
Kii, Isao [1 ,3 ,4 ]
机构
[1] Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, Lab Drug Target Res, 8304 Minami Minowa, Nagano 3994598, Japan
[2] RIKEN, Lab Epigenet Drug Discovery, Ctr Biosyst Dynam Res, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan
[3] Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, 8304 Minami Minowa, Nagano 3994598, Japan
[4] RIKEN, Lab Chem Biol, Ctr Biosyst Dynam Res, Chuo Ku, 6-7-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan
[5] Tokyo Med & Dent Univ TMDU, Inst Biomat & Bioengn, Lab Chem Biosci, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo, Japan
[6] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan
关键词
DYRK1A; Folding intermediate; Autophosphorylation; FINDY; Alzheimer's disease; Down syndrome; DOWN-SYNDROME CANDIDATE; PROTEIN-KINASE; MOUSE MODEL; MURINE MODEL; DRUG-TARGET; CYCLIN D1; ACTIVATION; AUTOPHOSPHORYLATION; OVEREXPRESSION; REVEALS;
D O I
10.1016/j.ejmech.2021.113948
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
DYRK1A phosphorylates proteins involved in neurological disorders in an intermolecular manner. Meanwhile, during the protein folding process of DYRK1A, a transitional folding intermediate catalyzes the intramolecular autophosphorylation required for the "one-off" inceptive activation and stabilization. In our previous study, a small molecule termed FINDY (1) was identified, which inhibits the folding intermediate-catalyzed intramolecular autophosphorylation of DYRK1A but not the folded state-catalyzed intermolecular phosphorylation. However, the structural features of FINDY (1) responsible for this intermediate-selective inhibition remain elusive. In this study, structural derivatives of FINDY (1) were designed and synthesized according to its predicted binding mode in the ATP pocket of DYRK1A. Quantitative structure-activity relationship (QSAR) of the derivatives revealed that the selectivity against the folding intermediate is determined by steric hindrance between the bulky hydrophobic moiety of the derivatives and the entrance to the pocket. In addition, a potent derivative 3 was identified, which inhibited the folding intermediate more strongly than FINDY (1); it was designated as dp-FINDY. Although dp-FINDY (3) did not inhibit the folded state, as well as FINDY (1), it inhibited the intramolecular autophosphorylation of DYRK1A in an in vitro cell-free protein synthesis assay. Furthermore, dp-FINDY (3) destabilized endogenous DYRK1A in HEK293 cells. This study provides structural insights into the folding intermediate-selective inhibition of DYRK1A and expands the chemical options for the design of a kinase inhibitor. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs
    Ramesh, Muthusamy
    Muthuraman, Arunachalam
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2020, 23 (09) : 887 - 897
  • [32] Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity
    Tu, Huang-Ju
    Su, Chih-Jou
    Peng, Chao-Shiang
    Lin, Tony Eight
    HuangFu, Wei-Chun
    Hsu, Kai-Cheng
    Hwang, Tsong-Long
    Pan, Shiow-Lin
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2023, 31 (02) : 358 - 370
  • [33] Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's?
    Smith, Breland
    Medda, Federico
    Gokhale, Vijay
    Dunckley, Travis
    Hulme, Christopher
    ACS CHEMICAL NEUROSCIENCE, 2012, 3 (11): : 857 - 872
  • [34] Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
    Ogawa, Yasushi
    Nonaka, Yosuke
    Goto, Toshiyasu
    Ohnishi, Eriko
    Hiramatsu, Toshiyuki
    Kii, Isao
    Yoshida, Miyo
    Ikura, Teikichi
    Onogi, Hiroshi
    Shibuya, Hiroshi
    Hosoya, Takamitsu
    Ito, Nobutoshi
    Hagiwara, Masatoshi
    NATURE COMMUNICATIONS, 2010, 1
  • [35] A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition
    Kim, Hyeongki
    Lee, Kyu-Sun
    Kim, Ae-Kyeong
    Choi, Miri
    Choi, Kwangman
    Kang, Mingu
    Chi, Seung-Wook
    Lee, Min-Sung
    Lee, Jeong-Soo
    Lee, So-Young
    Song, Woo-Joo
    Yu, Kweon
    Cho, Sungchan
    DISEASE MODELS & MECHANISMS, 2016, 9 (08) : 839 - 848
  • [36] Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay
    Wang, Di
    Wang, Fei
    Tan, Yexiong
    Dong, Liwei
    Chen, Lei
    Zhu, Weiliang
    Wang, Hongyang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 168 - 171
  • [37] Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
    Melchior, Benoit
    Mittapalli, Gopi Kumar
    Lai, Carolyn
    Duong-Polk, Karen
    Stewart, Joshua
    Guner, Bora
    Hofilena, Brian
    Tjitro, Amanda
    Anderson, Scott D.
    Herman, David S.
    Dellamary, Luis
    Swearingen, Christopher J.
    Sunil, K. C.
    Yazici, Yusuf
    AGING CELL, 2019, 18 (05)
  • [38] Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A
    Pons-Espinal, Meritxell
    Martinez de Lagran, Maria
    Dierssen, Mara
    NEUROBIOLOGY OF DISEASE, 2013, 60 : 18 - 31
  • [39] 10-lodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A
    Falke, Hannes
    Chaikuad, Apirat
    Becker, Anja
    Loaec, Nadege
    Lozach, Olivier
    Abu Jhaisha, Samira
    Becker, Walter
    Jones, Peter G.
    Preu, Lutz
    Baumann, Knut
    Knapp, Stefan
    Meijer, Laurent
    Kunick, Conrad
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (07) : 3131 - 3143
  • [40] Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation
    Kumar, Kunal
    Wang, Peng
    Sanchez, Roberto
    Swartz, Ethan A.
    Stewart, Andrew F.
    Devita, Robert J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (17) : 7687 - 7699